Mayr Patrick, Lutz Mathias, Schmutz Maximilian, Hoeppner Jens, Liesche-Starnecker Friederike, Schlegel Jürgen, Gaedcke Jochen, Claus Rainer
Department of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Department of Surgery, Medical Faculty Schleswig-Holstein, University of Schleswig-Holstein, Lübeck, Germany.
Front Oncol. 2022 Aug 2;12:905103. doi: 10.3389/fonc.2022.905103. eCollection 2022.
JC virus reactivation causing progressive multifocal leukoencephalopathy (PML) occurs preferentially in human immunodeficiency virus (HIV) positive individuals or patients suffering from hematologic neoplasms due to impaired viral control. Reactivation in patients suffering from solid malignancies is rarely described in published literature.
Here we describe a case of PML in a male patient suffering from esophageal cancer who underwent neoadjuvant radiochemotherapy and surgical resection in curative intent resulting in complete tumor remission. The radiochemotherapy regimen contained carboplatin and paclitaxel (CROSS protocol). Since therapy onset, the patient presented with persistent and progredient leukopenia and lymphopenia in absence of otherwise known risk factors for PML. Symptom onset, which comprised aphasia, word finding disorder, and paresis, was apparent 7 months after therapy initiation. There was no relief in symptoms despite standard of care PML directed supportive therapy. The patient died two months after therapy onset.
PML is a very rare event in solid tumors without obvious states of immununosuppression and thus harbors the risk of unawareness. The reported patient suffered from lymphopenia, associated with systemic therapy, but was an otherwise immunocompetent individual. In case of neurologic impairment in patients suffering from leukopenia, PML must be considered - even in the absence of hematologic neoplasia or HIV infection.
JC病毒再激活导致进行性多灶性白质脑病(PML),这种情况优先发生在人类免疫缺陷病毒(HIV)阳性个体或因病毒控制受损而患有血液系统肿瘤的患者中。实体恶性肿瘤患者的病毒再激活在已发表的文献中很少有描述。
在此,我们描述了一例食管癌男性患者发生PML的病例,该患者接受了新辅助放化疗及根治性手术切除,肿瘤完全缓解。放化疗方案包含卡铂和紫杉醇(CROSS方案)。自治疗开始以来,患者在无其他已知PML危险因素的情况下,出现持续性且进行性加重的白细胞减少和淋巴细胞减少。症状发作包括失语、找词困难和轻瘫,在治疗开始7个月后明显出现。尽管采用了标准的针对PML的支持性治疗,症状仍未缓解。患者在治疗开始两个月后死亡。
PML在无明显免疫抑制状态的实体肿瘤中是非常罕见的事件,因此存在未被认识的风险。报告的该患者存在与全身治疗相关的淋巴细胞减少,但在其他方面免疫功能正常。对于白细胞减少的患者出现神经功能损害时,即使没有血液系统肿瘤或HIV感染,也必须考虑PML。